Share on StockTwits

Analysts at Jefferies Group dropped their target price on shares of Merck & Co. (NYSE:MRK) from $63.00 to $60.00 in a research report issued to clients and investors on Monday. Jefferies Group’s target price indicates a potential upside of 6.10% from the stock’s previous close.

Merck & Co. (NYSE:MRK) traded up 0.69% on Monday, hitting $56.94. 1,583,956 shares of the company’s stock traded hands. Merck & Co. has a one year low of $44.62 and a one year high of $59.84. The stock has a 50-day moving average of $57.94 and a 200-day moving average of $56.57. The company has a market cap of $164.3 billion and a P/E ratio of 29.79.

Merck & Co. (NYSE:MRK) last released its earnings results on Tuesday, July 29th. The company reported $0.85 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.80 by $0.05. The company had revenue of $10.93 billion for the quarter, compared to the consensus estimate of $10.60 billion. During the same quarter last year, the company posted $0.84 earnings per share. Merck & Co.’s revenue was down .7% compared to the same quarter last year. On average, analysts predict that Merck & Co. will post $3.49 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Tuesday, October 7th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a dividend yield of 3.11%. The ex-dividend date is Thursday, September 11th.

Several other analysts have also recently commented on the stock. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Merck & Co. in a research note on Thursday, July 31st. They now have a $59.00 price target on the stock, up previously from $56.00. Separately, analysts at BMO Capital Markets raised their price target on shares of Merck & Co. from $60.00 to $62.00 in a research note on Thursday, July 31st. Finally, analysts at Mainfirst upgraded shares of Merck & Co. from an “underperform” rating to an “outperform” rating in a research note on Monday, July 28th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $60.54.

In other Merck & Co. news, Insider Adele D. Ambrose unloaded 28,669 shares of Merck & Co. stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $56.64, for a total transaction of $1,623,812.16. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Merck & Co, Inc (NYSE:MRK), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.